The aim of this study is to produce the proof of concept in vitro and in vivo that GRK2 inhibition through KRX-C7 represents an effective therapeutic approach for the treatment of T2DM with positive effects on diabetic cardiomyopathy. Here, GRK2 is linked to diabetic cardiomyopathy.